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Abstract
The role of the epithelial-to-mesenchymal transition (EMT) during hepatocellular carcinoma (HCC) progression is well
established, however the regulatory mechanisms modulating this phenomenon remain unclear. Here, we demonstrate that
transcription factor glioma-associated oncogene 1 (GLI1) modulates EMT through direct up-regulation of SNAI1 and serves
as a downstream effector of the transforming growth factor-b1 (TGFb1) pathway, a well-known regulator of EMT in cancer
cells. Overexpression of GLI1 increased proliferation, viability, migration, invasion, and colony formation by HCC cells.
Conversely, GLI1 knockdown led to a decrease in all the above-mentioned cancer-associated phenotypes in HCC cells.
Further analysis of GLI1 regulated cellular functions showed that this transcription factor is able to induce EMT and
identified SNAI1 as a transcriptional target of GLI1 mediating this cellular effect in HCC cells. Moreover, we demonstrated
that an intact GLI1-SNAI1 axis is required by TGFb1 to induce EMT in these cells. Together, these findings define a novel
cellular mechanism regulated by GLI1, which controls the growth and EMT phenotype in HCC.
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(EMT), has been increasingly recognized to occur during the
progression of various carcinomas, including HCC [8,9]. It has
been proposed that EMT is one of the key mechanisms through
which metastasis occurs in different tumors, beginning with the
disruption of intercellular contacts and the enhancement of cell
motility, thus resulting in the release of cancer cells from the
primary tumor. Several studies have shown that different pathways
are capable of inducing the EMT phenotype in HCC cells [8,10–
12], however, the specific mechanisms regulating this phenomenon are still incompletely understood. We have previously
reported that the expression of GLI1, a well-known oncogenic
transcription factor, in HCC tissues was positively associated with
the EMT phenotype [11]. Here, we expanded on these findings
and investigated the functional role of GLI1 in HCC and the
interaction between GLI1, TGFb1 and SNAI1 in the context of

Introduction
HCC is the third most frequent cause of cancer death, with an
estimated 750,000 new cases per year [1]. Liver resection and
transplantation are currently the main curative therapies for HCC
[2,3]. Unfortunately, there is a high rate of postsurgical recurrence
after resection due to metastatic dissemination of the tumor prior
to resection or to the development of new neoplastic changes in
the remaining cirrhotic liver [4,5]. Consequently, the long-term
prognosis of most patients with HCC is extremely poor [6,7].
Hence, it is critical to improve our understanding of the molecular
mechanisms determining HCC recurrence and metastasis to
develop new therapeutic strategies for this disease.
The transition of epithelial cells to a mesenchymal phenotype,
which is designated as epithelial-to-mesenchymal transition
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was decreased about 90% after transfection with GLI1 ASO
(P = 0.002; Figure S3A). Western immunoblotting confirmed the
decrease in GLI1 protein expression in SNU398-GLI1 ASO cells
(Figure S3A). A GLI reporter luciferase assay was used to confirm
the functional consequence of transfection with GLI1 ASO.
Luciferase activity decreased significantly in SNU398 GLI1 ASO
transfected cells compared to control ASO transfected cells
(P = 0.002; Figure S3B and data not shown). Cell proliferation as
measured by the BrdU ELISA assay (P = 0.004; Figure 1A), cell
viability as measured by the MTT assay (P,0.0001 at all four time
points; Figure 1B), cell migration (P,0.05 and P,0.05, respectively at 24 and 48 hrs; Figure 1C), and cell invasion (P,0.05;
Figure 1D) were all significantly decreased in SNU398-GLI1 ASO
cells as compared to SNU398-Control ASO cells. Similarly, the
soft agar colony formation assay showed that fewer colonies were
formed by SNU398-GLI1 ASO transfected cells compared to the
control cells (P = 0.04; Figure 1E).
To determine the clinical relevance of the above-mentioned
effects of GLI1 in HCC cells, we examined the association
between GLI1 mRNA expression and HCC recurrence by gene
expression microarray. GLI1 mRNA was detected in 74 of 139
HCC patients and there was increased GLI1 expression in tumor
compared to benign tissues in 43 (58.1%) of the HCCs. The 139
HCC patients were classified into two groups: GLI1 high expresser
and GLI1 low/non expresser. The GLI1 high expresser group
included patients with higher GLI1 expression in tumor tissues,
while the GLI1 low/non expresser group included patients with
lower or no GLI1 expression in tumor tissues. As shown in Table
S1, there were no significant differences in demographic and
clinical characteristics between these two groups except for
vascular invasion, which was more prevalent in high GLI1
expressing tumors (P = 0.05). Although there was no significant
difference in overall survival time between the two groups, the 5year recurrence rate in the GLI1 high expresser group was 85%
compared to 59% in the GLI1 low/non expresser group
(P = 0.007, Chi square test), and comparison of Kaplan Meier
recurrence-free survival curves showed a tendency toward a more
rapid rate of tumor recurrence in patients with GLI1 high
expressing tumors (HR = 1.69; 95% CI: 0.9, 3.9; P = 0.09;
Figure 2A). The median recurrence-free survival was 25 months
in the GLI1 high expresser group, while the median recurrencefree survival in the GLI1 low/non expresser group was 47 months
(Figure 2A). When patients were classified into two groups by
GLI1 expression, a Low GLI1 and High GLI1 group using the
median ratio of tumor/benign GLI1 expression as the cut-off
value, most demographic and clinical characteristics were similar
in the two groups, except that there were more HCC patients with
alcoholic liver disease in the High GLI1 group (P,0.05) (Table
S2). Consistent with the prior results, tumor vascular invasion was
more frequent in High GLI1 expressing HCCs than in Low GLI1
expressing HCCs (22.9% vs. 14.3%), but this difference was not
statistically significant (Table S2). The 5-year recurrence rate in
the High GLI1 group was 85% compared to 42% in the Low
GLI1 group. Comparison of the Kaplan Meier curves of
recurrence-free survival showed a significantly more rapid rate
of tumor recurrence in patients with tumors expressing high levels
of GLI1 (HR = 2.63; 95% CI: 1.0, 6.5; P = 0.04; Median
recurrence-free survival was 30 months in the High GLI1 group
vs. 85 months in the Low GLI1 group; Figure 2B). Together these
findings support a novel role for GLI1 in HCC pathogenesis and
suggest tumor recurrence as one of the biological features that may
be modulated by this transcription factor.

the EMT, and finally defined novel molecular events underlying
the EMT in HCC. These findings further support the role of the
transcription factor GLI1 in the regulation of EMT and expand
the repertoire of molecules including ZEB1, ZEB2, SNAI2 and
TWIST [13–15] that act in concert with TGFb1 and GLI1
pathways to control EMT in cancer cells.

Results
GLI1 enhances HCC colony formation and promotes cell
proliferation, viability, migration and invasion
To develop in vitro models xamining the mechanistic role of
GLI1 in HCC biology, we determined the mRNA expression of
GLI1 in 11 different human HCC cell lines and normal human
hepatocytes by qRT-PCR. Five of the HCC cell lines (PLC/PRF5,
SNU182, SNU398, SNU449, and SNU475) express GLI1 mRNA
at a higher level than normal human hepatocytes, with four of the
cell lines expressing GLI1 at more than two-fold the level in
normal hepatocytes (Figure S1). SNU398, the highest expressing
cell line, expressed GLI1 mRNA at over 55-times the level in
normal hepatocytes. Cell lines expressing lower GLI1 mRNA
include Hep3B, HepG2, Huh7, SK-HEP-1, SNU387 and
SNU423 (Figure S1). We confirmed that GLI1 protein expression
mirrors the mRNA expression in a subset of HCC cell lines using
Western blot analysis. Similar to the data shown in Figure S1,
SNU398 shows the highest GLI1 protein expression and Huh7 is
among the HCC cells with the lowest GLI1 expression (Figure S2).
We selected Huh7 for GLI1 overexpression experiments; and
SNU398 cells to be transfected with GLI1 antisense oligonucleotides (ASO) in knockdown experiments.
Initially, to investigate the effect of GLI1 on HCC cell growth,
we overexpressed a FLAG-tagged expression construct of this
transcription factor. Overexpression of GLI1 was confirmed by
qRT-PCR and Western immunoblotting. Western immunoblotting and RT-PCR confirmed that Huh-7 cells transfected with
GLI1 (Huh7-GLI1) cells expressed GLI1 protein at a high level
compared to the Huh7 cells transfected with parental vector
(Huh7-Vector) (Figure S3A). Similarly, GLI-dependent reporter
activity was increased after transfection of Huh7 and SNU423 cells
with GLI1, confirming the functional capacity of the expressed
protein (P,0.0001; Figure S3B and data not shown).
Next, we quantitated cell proliferation using the BrdU
incorporation assay and cell viability using the MTT assay.
Huh7-GLI1 cells showed significantly greater BrdU incorporation
than Huh7-Vector cells (P = 0.0005; Figure 1A). Overexpression of
GLI1 also significantly increased the viability of Huh7 cells as
assessed by the MTT assay (P,0.0001 at all four time points;
Figure 1B). To determine whether ectopic expression of GLI1
increases HCC cell migration, we used the wound-healing assay
and showed that the migration rate of Huh7-GLI1 cells was
significantly higher than that of Huh7 Vector cells at both 24 and
48 hours after scratching (P = 0.005 and P = 0.004, respectively;
Figure 1C). To determine the effect of GLI1 on HCC invasion, we
performed a quantitative transwell chamber invasion assay.
Overexpression of GLI1 significantly increased the invasive ability
of Huh7 cells (P,0.05; Figure 1D). Further characterization of the
cellular functions regulated by GLI1 using the soft agar colony
formation assay showed there were significantly more cell colonies
formed by Huh7 cells stably-expressing GLI1 (P = 0.04; Figure 1E).
To complement these overexpression studies, we evaluated the
effect of suppression of GLI1 on the cancer phenotype by
transfecting the endogenously high GLI1-expressing SNU398 cells
with GLI1 ASO. Suppression of GLI1 mRNA expression was
confirmed by qRT-PCR 24 hours after transfection. GLI1 mRNA
PLOS ONE | www.plosone.org
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Figure 1. GLI1 promotes cell proliferation, viability, migration, invasion and colony formation of HCC cells. (A) Overexpression of GLI1
increases BrdU incorporation of Huh7 cells and silencing GLI1 expression in SNU398 cells decreases BrdU incorporation. (B) As assessed by the MTT
assay, cell viability is increased at 48, 72 and 96 hours by overexpression of GLI1 in Huh7 cells and decreased at 24, 48, 72 and 96 hours by
knockdown of GLI1 in SNU398 cells. (C) As assessed by the wound-healing assay, at both 24 and 48 hours, cell migration rate is increased in Huh7
cells by overexpression of GLI1 and decreased in SNU398 cells by silencing GLI1 expression. (D) Cell invasion is increased by overexpression of GLI1 in
Huh7 cells and decreased by knockdown of GLI1 in SNU398 cells. (E) Overexpression of GLI1 promotes colony formation of Huh7 cells; in contrast,
knockdown of GLI1 represses colony formation of SNU398 cells.
doi:10.1371/journal.pone.0049581.g001

GLI1 decreased E-cadherin protein expression and increased Ncadherin and Vimentin protein expression as shown by both
Western immunoblotting and immunofluorescence (Figure 4B and
5A). Additional experiments performed in cells with endogenous
low levels of GLI1: SNU423 and SK-HEP-1, show similar EMT
changes upon GLI1 overexpression (Figure S5). On the other
hand, knockdown of GLI1 in SNU398 cells up-regulated Ecadherin, and down-regulated both N-cadherin and Vimentin
(P = 0.004, P,0.0001 and P,0.0001, respectively; Figure 4A, 4B
and 5B) at both the mRNA and protein levels. Similar results were
obtained in SNU449 and SNU 475 cells (Figure S5). These results,
which show reversal of the EMT phenotype after knockdown of
GLI1 in SNU398 cells, are consistent with the observed decreases
in cell migration and invasion, two cellular events associated with
EMT changes in cancer cells (Figure 1C and 1D).
To determine whether SNAI1 plays a critical role in the GLI1induced EMT phenotype in HCC, we silenced SNAI1 expression
in Huh7 cells overexpressing GLI1 using siRNA. Knockdown of
SNAI1 was confirmed by qRT-PCR and Western immunoblotting
(Figure 6A and 6B). The mRNA and protein expression of Ecadherin were both significantly increased in cells transfected with
SNAI1 siRNA, while the expression of both N-cadherin and
Vimentin were decreased at both the mRNA and protein levels
(Figure 6A, and B, lower panel). These data show that knockdown
of SNAI1 can inhibit the EMT phenotype induced by GLI1 in
HCC, which further supports the hypothesis that SNAI1 could
mediate GLI1-induced EMT in HCC.

GLI1 induces EMT in HCC cells through a SNAI1dependent mechanism
Analysis of the mechanism underlying the effect of GLI1 on
HCC cell growth showed that SNAI1, a target of this transcription
factor [16,17] was significantly increased in Huh7 cells overexpressing GLI1 at the mRNA (P = 0.0022; Figure 3A) and protein
levels, as confirmed by immunofluorescence (Figure 3B, upper
right panel) and Western immunoblotting (Figure 3B, lower right
panel). Consistent with the results in Huh7 cells, knockdown of
GLI1 in SNU398 cells significantly reduced SNAI1 mRNA
expression by about 85% (P = 0.002; Figure 3A, left panel) and
also decreased SNAI1 protein levels (Figure 3B, left panel).
Knockdown of GLI1 also reduced SNAI1 expression in SNU449
and SNU475 HCC cells (Figure S4). Finally, chromatin immunoprecipitation (ChIP) assays carried out in Huh7 cells showed
that GLI1 can bind to a region in the SNAI1 promoter located
21,417/21,214 bp upstream of the transcriptional start site
(Figure 3C). Bioinformatics analysis of this region in the SNAI1
promoter demonstrates the presence of two candidate GLI1
bindings sites in this area (Figure 3D). Functional validation of
these sites using luciferase reporter assays shows that GLI1 is not
longer able to induce the activity of the SNAI1 promoter in a
reporter construct lacking these two GLI1 bindings sites
(Figure 3E). These data strongly suggest that GLI1 directly upregulates SNAI1 expression in HCC and define SNAI1 as a direct
target of the GLI1 transcription factor in HCC cells.
The effect of GLI1 on SNAI1 expression prompted us to
examine the effect of GLI1 on EMT by assessing the mRNA and
protein expression of the well-established epithelial marker Ecadherin and the mesenchymal markers N-cadherin and Vimentin. E-cadherin mRNA was significantly decreased in Huh7-GLI1
cells compared to Huh7-Vector cells (P = 0.002; Figure 4A), in
contrast, the mRNA levels of N-cadherin and Vimentin were both
significantly up-regulated by overexpression of GLI1 (P = 0.002;
Figure 4A). Consistent with the mRNA results, overexpression of

The GLI1-SNAI1 axis is required for TGFb1 EMT induction
To assess whether this GLI1-SNAI1 axis can function as an
effector of pathways that control EMT in HCC cells we examined
the effect of knockdown of GLI1 on the EMT induced by TGFb1,
a known regulator of EMT in HCC cells [12,18]. Treatment of
Huh7 cells with TGFb1 led to up-regulation of GLI1 expression
(Figure 7A). Concomitantly, TGFb1 significantly induced the

Figure 2. GLI1 expression is positively associated with HCC recurrence. (A) Tumor recurrence after surgical resection in 139 patients with
HCCs. Differences between the Kaplan-Meier curves of patients in the GLI1 high expresser group and those in GLI1 low/non expresser group using
the log rank test. (B) Tumor recurrence after surgical resection in the 35 patients from the high GLI1 group and in the 35 patients from the low GLI1
group. Increased GLI1 expression in HCC tissues was significantly correlated with more rapid tumor recurrence after surgical resection of the primary
tumor.
doi:10.1371/journal.pone.0049581.g002
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Figure 3. SNAI1 is a transcriptional target of GLI1 in HCC cells. (A) As measured by both qRT-PCR, SNAI1 expression is increased by
overexpression of GLI1 in Huh7 cells and decreased by knockdown of GLI1 in SNU398 cells. (B) Western immunoblotting (lower panel) and
immunofluorescence staining (upper panel) confirm that SNAI1 protein expression is increased by overexpression of GLI1 in Huh7 cells (left panel)
and decreased by knockdown of GLI1 in SNU398 cells (right panel). (C) ChIP assay verifies that GLI1 protein binds to the SNAI1 promoter. PCR was
performed using a specific set of primers as indicated in Methods. (D) Bioinformatics analysis of the SNAI1 promoter identified candidate GLI (G)
binding sites; (TSS = transcription start site). The positive amplicon for the ChIP assay is marked 21,417/21,214 bp upstream of transcription start site
(E) Relative changes in luciferase activity in Huh7 (left) and SNU398 (right) cells transfected with the WT and GLI mutant SNAI1 promoter luciferase
reporter and control vector or GLI1.
doi:10.1371/journal.pone.0049581.g003

TGFb1 has also been shown to promote tumor progression and
metastasis of established cancers, in part by the induction of the
EMT [18,27,28]. This apparent conversion in TGFb1 function
after tumor initiation is known as the ‘‘TGFb1 paradox’’ [29–31].
It is important to understand the downstream effectors of the
TGFb1 signaling pathway and identify the ‘‘molecular switch or
switches’’ mediating the ‘‘TGFb1 paradox’’. TGFb1 is considered
a major driver of the EMT in HCCs [12,18,32]. While
investigating the mechanistic interactions between TGFb1 and
GLI1 signaling during induction of the EMT in HCCs, we found
that induction of the EMT in Huh7 cells by TGFb1 was associated
with a significant increase in GLI1 expression. When GLI1
expression was silenced, TGFb1 induction of the EMT phenotype
was abrogated and the expression of SNAI1, a known downstream
effector of TGFb1-induced EMT, was also decreased.
SNAI1 is an effector transcription factor that has been shown to
induce the EMT through direct suppression of E-cadherin
transcription in cancer and thus contribute to tumor cell growth,
migration and invasion [33–34]. In this study, we found that
overexpression of GLI1 up-regulated SNAI1 in Huh7 cells and
knockdown of GLI1 down-regulated SNAI1 in SNU398 cells.
Further, we also confirmed by ChIP assay that GLI1 directly binds
to the SNAI1 promoter in HCC cells. These data show that GLI1
can increase SNAI1 expression in HCC by directly promoting its
transcription. Next, by assessing the expression of EMT markers
and differences in cell migration and invasion, we found that
overexpression of GLI1 induced a significant EMT phenotype in
Huh7 cells, while knockdown of GLI1 in SNU398 cells reversed
their original mesenchymal-like phenotype. Those results confirm
that GLI1 can induce the EMT in HCC. To further investigate
whether SNAI1 contributes to the GLI1 induced EMT, we
silenced SNAI1 expression in Huh7 cells transfected with a GLI1
expressing plasmid and found that the EMT phenotype was
reverse d. These results are in agreement with previous studies
demonstrating that GLI1 controls the expression of SNAI1 and
uses this transcription factor as a cellular effector to regulate gene
expression and transformation [16,35–37]. Reports by Li and
colleagues showed that GLI1 requires the induction of SNAI1 to
promote transformation in epithelial cells and to regulate the
activity Wnt oncogenic signaling [38]. Similarly, Kuphal et al.
demonstrate that GLI1 controls cell proliferation via a SNAI1dependent regulation of CYLD [37]. Together these results
strongly suggest that the induction of the EMT by GLI1 in HCC is
mediated through SNAI1.
In conclusion, this study shows that GLI1 promotes colony
formation, proliferation, viability, migration and invasion of HCC
cells, which may contribute to HCC recurrence. Further, we show
that GLI1 induces the EMT through direct up-regulation of the
EMT-inducer SNAI1. The GLI1-SNAI1 axis also appears to be
involved in the mechanism by which TGFb1 induces the EMT in
HCC, which suggests that up-regulation of GLI1 may be a
potential ‘‘switch’’ for the ‘‘TGFb1 paradox’’. Taken together, our
data imply that GLI1 plays an important part in mediating HCC
progression and may serve as a therapeutic target for HCC.

expression of N-cadherin, Vimentin and SNAI1 (Figure 7A and
Figure S5). Although no significant difference was found in Ecadherin expression, the effects on N-cadherin and Vimentin still
indicate at least a partial TGFb1 induction of the EMT phenotype
in Huh7 cells. To investigate whether GLI1 is involved in TGFb1induced EMT in HCC cells, we transfected Huh7 cells with GLI1
ASO before TGFb1 treatment. The GLI1 ASO suppressed the
TGFb1-induction of GLI1 expression (Figure 7B). Concomitantly,
SNAI1 expression was significantly decreased (Figure 7B). Consistent with these results, transfection of TGFb1-treated Huh7 cells
with GLI1 ASO significantly increased E-cadherin expression and
decreased the expression of both N-cadherin and Vimentin
(Figure 7C). These data suggest that the GLI1-SNAI1 axis plays
an important role in the mechanism by which TGFb1 induces the
EMT in HCC cells and define GLI1 as a central mediator of this
cellular process.

Discussion
The natural history of HCC is characterized by rapidly
infiltrating growth and early metastasis. Due to these pathologic
features, approximately 60–80% of HCC patients are diagnosed at
an advanced stage at which they are not candidates for curative
treatments [19,20]. Achieving improvements in therapy will
require a better understanding of the molecular mechanisms
regulating HCC invasion and metastasis. The EMT has been
shown to contribute to tumor formation and metastasis of HCC,
however, the mechanisms by which EMT is regulated in HCC
have not been completely elucidated [8,21–24]. We have found
that the transcription factor GLI1 expression was positively
associated with the EMT phenotype and with intrahepatic
metastasis and portal venous invasion of human HCCs [11]. In
this study, we show a new analysis of microarray expression data
demonstrating that GLI1 overexpression in HCC tissues is
associated with more rapid recurrence of HCC tumors after
surgery. Corresponding in vitro studies in cell line models of
overexpression or suppression of GLI1 expression showed that
overexpression of GLI1 increased proliferation, viability, migration, invasion and colony formation by HCC cells. Conversely,
GLI1 knockdown led to a decrease in these cancer-associated
phenotypes in HCC cells. GLI1 induced the EMT in HCC cells.
Further mechanistic studies identified SNAI1 as a transcriptional
target of GLI1 in HCC cells and showed that this GLI1-SNAI1
axis mediates the TGFb1-induced EMT in HCC cells. Thus, we
have defined a mechanism regulated by GLI1 controlling the
EMT in HCC cells. These results are in alignment with previous
reports suggesting that GLI1 promotes recurrence and metastasis
in other tumor types such as colon cancer [25]. Together, our
findings demonstrate a central role for GLI1 in regulation of the
EMT in liver cancer and expand the repertoire of pathways that
modulate this cellular process.
In most models of epithelial cell carcinogenesis, TGFb1 inhibits
cell proliferation by arresting tumor cells in the G1 phase [26],
thus functioning as a tumor suppressor. On the other hand,
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Figure 4. GLI1 induces EMT in HCC ells. (A) As assessed by qRT-PCR, overexpression of GLI1 decreases E-cadherin mRNA expression and
increases the mRNA expression of both N-cadherin and Vimentin in Huh7 cells, while knockdown of GLI1 increases E-cadherin mRNA expression and
decreases the mRNA expression of both N-cadherin and Vimentin in SNU398 cells. (B) As assessed by Western immunoblotting followed by
densitometry analysis, overexpression of GLI1 decreases E-cadherin expression and increases the expression of both N-cadherin and Vimentin in
Huh7 cells, while knockdown of GLI1 increases E-cadherin expression and decreases the expression of both N-cadherin and Vimentin in SNU398 cells.
doi:10.1371/journal.pone.0049581.g004

Figure 5. Immunofluorescence studies confirm the role of GLI1 in the regulation of EMT in HCC cells. (A) As assessed by
immunofluorescence staining and confocal microscopy, overexpression of GLI1 decreases E-cadherin protein expression and increases the protein
expression of both N-cadherin and Vimentin in Huh7 cells. (B) As assessed by immunofluorescence staining and confocal microscopy, knockdown of
GLI1 (GLI1 ASO) increases E-cadherin protein expression and decreases the protein expression of both N-cadherin and Vimentin in SNU398 cells. DAPI
was used as nuclear staining.
doi:10.1371/journal.pone.0049581.g005
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Figure 6. Knockdown of SNAI1 reverses the EMT phenotype induced by GLI1 in HCC cells. (A) SNAI1 siRNA decreases SNAI1 expression in
Huh7 cells transfected stably with GLI1 expressing plasmid. SNAI1 siRNA increases E-cadherin expression (B) and decreases the expression of both Ncadherin (C) and Vimentin (D) in Huh7 cells transfected stably with GLI1 expressing plasmid.
doi:10.1371/journal.pone.0049581.g006

Verbal consent was obtained from patients and documented in the
patient medical record as instructed and approved by the Mayo
Clinic Institutional Review Board from 2001 to 2003. Beginning
in 2003, the Mayo Clinic Institutional Review Board required
written informed consent and this was obtained and the signed
consent form was scanned into each patient’s electronic medical
record.

Materials and Methods
Ethics Statement
The microarray gene expression analysis of human HCCs
reported in this study was approved by the Institutional Review
Boards of the Mayo Clinic, the Cancer Institute of the Chinese
Academy of Medical Sciences, the University of Leuven and the
US National Cancer Institute. Deidentified anonymized samples
were either from patients who had provided verbal or written
informed consent or were surgical waste tissues from deceased
patients, which were used with Institutional Review Board
approval. Verbal consent was the standard requirement of the
Mayo Clinic Institutional Review Board at the time the Mayo
Hepatobiliary Neoplasia Biorepository was initiated in 2001.
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Cell Culture and Treatment
Ten HCC cell lines (Hep3B, HepG2, PLC/PRF5, SK-HEP-1,
SNU398, SNU423, SNU387, SNU475, SNU182 and SNU449)
were obtained from the American Type Culture Collection
(Manassas, VA) and were cultured as recommended. Huh7 was
obtained from the Japan Health Science Research Resources Bank
9
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Figure 7. GLI1 is induced by TGFb1 and mediates the mechanism by which TGFb1 induces EMT in HCC cells. (A) TGFb1 increases GLI1
expression in Huh7 cells. And TGFb1 is also found to decrease E-cadherin expression, while increasing the expression of N-cadherin, Vimentin and
SNAI1 in Huh7 cells. (B) Suppressing the TGFb1 induced up-regulation of GLI1 in Huh7 cells by GLI1 ASO decreased the expression of both GLI1 and
SNAI1 in Huh7 cells. (C) Suppressing the TGFb1 induced up-regulation of GLI1 in Huh7 cells by GLI1 ASO increases E-cadherin expression and
decreases the expression of both N-cadherin and Vimentin.
doi:10.1371/journal.pone.0049581.g007

(HSRRB, Osaka, Japan). Normal human hepatocytes were
isolated and cultured from a patient without any known liver
disease at Mayo Clinic, Rochester, MN. For TGFb1 treatment,
Huh7 cells were incubated with 1% FBS for 24 hours and
stimulated with 10 ng/ml of TGF-b1 for 72 hours.

GLI1 Antisense Oligonucleotide and SNAI1 siRNA
Transfection
GLI1 antisense oligonucleotide (ASO) and negative control
ASO were obtained from ISIS Pharmaceuticals (Carlsbad, CA).
The details of these ASO have been reported previously [38]. We
transfected the GLI1 ASO into SNU398 cells using Lipofectamine
2000 (Invitrogen, Carlsbad, CA) following the manufacturer’s
instruction and designated the cells as GLI1-knockdown SNU398
cells (SNU398-GLI1 ASO). Similarly, negative control ASO was
transfected into SNU398 cells (SNU398-control ASO). SNAI1
siRNA (sc-38398) was obtained from Santa Cruz Bio (Santa Cruz,
CA). Using the siPORTTM NeoFXTM Transfection Agent
(Applied Biosystems, Carlsbad, CA), we transfected both SNAI1
siRNA and scrambled siRNA into Huh7 cells which had been
previously transfected with GLI1-expressing plasmid according to
the instruction manual.

GLI1-expressing Plasmid Construction and Stable
Transfection
The cDNA of GLI1 was cloned into the pCMV-Tag2B vector
from Stratagene (Santa Clara, CA). GLI1-negative Huh7 cells
were stably transfected with the GLI1-expressing plasmid using
FuGENEH 6 Transfection Reagent (Roche, Indianapolis, IN) and
designated as Huh7 GLI1-expressing cells (Huh7-GLI1). Empty
pCMV-Tag2B vector was also transfected into Huh7 cells and
designated as Huh7 vector control cells (Huh7-Vector). Geneticin
(G418) from Invitrogen (Carlsbad, CA) at a dose of 600 mg/mL
was used to select stably expressing clones.

PLOS ONE | www.plosone.org
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FuGENEH 6 Transfection Reagent. Luciferase activity was
measured using the Dual-Luciferase Reporter assay from Promega
(Madison, WI) and normalized by protein quantification. Each
data point represents an average of six independent transfections.

Quantitative Real-time Reverse Transcription Polymerase
Chain Reaction (qRT-PCR)
Total RNA was extracted from HCC cell lines using the
RNeasy kit (Qiagen, Valencia, CA). cDNA synthesis was
performed using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Carlsbad, CA) to transcribe 2 mg of total
RNA. QRT-PCR was performed using ABI TaqMan assays in an
ABI 7300 system. The following ABI TaqMan probes were used:
18s rRNA, GLI1, SNAI1, E-cadherin, N-cadherin, and Vimentin.
The mRNA levels were normalized to 18s rRNA mRNA levels in
the same samples. Each measurement was performed 6 times.

Cell Proliferation and Viability Assays
After selection with G418 for two weeks or transient transfection, HCC cells were used in cell proliferation and cell viability
assays, respectively. For the proliferation assay, HCC cells were
seeded into 96-well plates at 5000 cells per well for 24 hours and
assessed using the BrdU ELISA kit (Roche, Indianapolis, IN). Soft
agar colony formation assays were performed in 96-well plates
using the CytoSelectTM 96-Well Cell Transformation Assay kit
(Cell Biolabs, San Diego, CA). Briefly, 5000 cells were seeded per
well in soft agar. After culturing cells for 6 days, we removed the
culture medium completely, solubilized the soft agar, lysed the
cells and added the CyQuant working solution. The results were
read with on a fluorescence plate reader using a 485/520 nm filter
set. The 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) assay was used to assess cell viability at 24, 48,
72 and 96 hours. The experiments were performed with at least
six replicates.

Western Immunoblotting
After selection with G418 for two weeks, whole cell protein
lysates were prepared from Huh-GLI1 cells and Huh7-Vector
cells. Whole cell protein lysates were prepared from SNU398GLI1 ASO cells and SNU398-control ASO cells cultured for 3
days after ASO transfection. Thirty micrograms of protein were
separated by denaturing gel electrophoresis. After transfer to
PVDF membrane, blots were probed overnight with the following
anti-human primary antibodies: rabbit polyclonal GLI1 antibody
(V812, 1:1000 dilution, Cell signaling, Danvers, MA), rabbit
monoclonal SNAI1 antibody (C15D3, 1:1000 dilution, Cell
signaling, Danvers, MA), mouse monoclonal E-cadherin antibody
(610181, 1:1000 dilution, BD Transduction Laboratory, San Jose,
CA), rabbit polyclonal N-cadherin antibody (sc7939, 1:200
dilution, Santa Cruz Bio, Santa Cruz, CA), rabbit monoclonal
Vimentin antibody (EPR3776, 1:1000, Abcam, Cambridge, MA)
and mouse monoclonal b-actin antibody (A-5316, 1:1000 dilution,
Sigma, St. Louis, MO). Blots were then incubated with anti-rabbit
(ALI3403, 1:5000 dilution, Biosource, Carlsbad, CA) or antimouse secondary antibodies conjugated with HRP (A3673, 1:5000
dilution, Sigma, St. Louis, MO), and signals were visualized using
the HyGLO HRP detection kit from Denville (Metuchen, NJ). bactin was measured to control for equal loading.

Migration Assay
HCC cells were plated onto 6-well plates and grown to
confluency. Scratch wounds were made with a 1000-mL-pipette
tip. The wounds were photographed with a phase-contrast
microscope at 0, 24 and 48 hours. Cell migration was quantitated
by measuring the width of the wounds. The experiments were
performed with at least six replicates.

Invasion Assay
We used the QCMTM 96-well cell invasion assay kit (Millipore,
Billerica, MA) for the invasion assays. HCC cells were first
incubated in serum-free medium for 24 hours. They were then
seeded into the invasion chamber at 16105 cells per well in serumfree medium. Medium with 10% fetal bovine serum (FBS) was
added into the lower chamber. After incubation for 24 hours at
37uC in a CO2 incubator (5% CO2), invaded HCC cells were
dislodged completely from underneath the invasion chamber using
the cell detachment solution and added to the lysis buffer/dye
solution mixture. The results were read with fluorescence plate
reader using a 480/520 nm filter set. The experiments were
performed with at least six replicates.

Immunofluorescence and Confocal Microscopy
Huh7-GLI1 cells, Huh7-Vector cells, SNU398-GLI1 ASO cells
and SNU398-control ASO cells were seeded on Lab-Tek II
Chamber Slides (Nalgene Nunc International, Naperville, IL) and
incubated for 24 hours. The cells were rinsed with Dulbecco’s PBS
(D-PBS) at room temperature and fixed for 20 min with 2.5%
formaldehyde in PIPES buffer. After rinsing with D-PBS, the cells
were incubated in blocking buffer (5% normal goat serum and 5%
glycerol in D-PBS) for 1 h at 37uC. The cells were then incubated
with primary antibodies against GLI1, SNAI1, E-cadherin, Ncadherin and Vimentin overnight at 4uC, rinsed 3 times, 10 min
each time, with D-PBS, and incubated with the appropriate FITClabeled secondary antibodies (Alexa Fluor 488, 1:1000 dilution,
Invitrogen, Carlsbad, CA) for 2 h at room temperature. Cells were
then washed three times for 5 min each time with D-PBS, rinsed
briefly with distilled water, mounted with DAPI on glass slides, and
examined by confocal microscopy.

Chromatin Immunoprecipitation Assay
Cells were fixed with 1% formaldehyde for 10 minutes at room
temperature and were processed further for immunoprecipitation
of chromatin. Chromatin immunoprecipitation (ChIP) was carried
out with the EZ-Magna ChIPTM Chromatin Immunoprecipitation
Kit (Millipore, Billerica, MA). Briefly, associated proteins were
cross-linked with 1% formaldehyde followed by cell lysis and DNA
shearing via 15 cycles of sonication. Cells were then immunoprecipitated using a GLI1 antibody (Cell Signaling Technology,
Danvers, MA), or normal rabbit IgG (Santa Cruz, CA). After that,
cross-links were removed and the immunoprecipitated DNA was
purified and subsequently amplified by PCR. The primers used to
detect the SNAI1 promoter are designed to amplify a region
spanning putative GLI binding elements identified within the
human SNAI1 promoter. The sequences are Forward: 59gtcttccttcacaggtggaaac-39 and Reverse: 59- cgtgaagatcctcgatcctgtg-39 producing an approximately 200 bp product. PCR

Luciferase Reporter Assay
GLI-Luciferase reporter plasmid containing eight consecutive
GLI-binding sites downstream of the luciferase gene (8XGLI) was
kindly provided by Dr. Chi-chung Hui (Research Institute,
Toronto, Ontario, Canada) [39]. The SNAI1 promoter wild type
and mutant promoters were kindly provided by Dr. Cynthia
Wetmore (Department of Oncology, St. Jude Children’s Research
Hospital, Memphis, TN) [17]. Cells plated in six-well plates at
60% confluency were transfected with the reporter plasmid using
PLOS ONE | www.plosone.org
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products were separated by electrophoresis and then visualized on
a 2% agarose gel.

with GLI1 mRNA in HCC cells. Tubulin was used as a
housekeeping control.
(TIF)

Microarray Gene Expression Profiling

Figure S3 GLI1 signaling can be efficiently modulated

HCC tumor and adjacent benign tissues were obtained from
139 individuals undergoing surgical resection for HCC at centers
in Asia, Europe, and the United States. The study was approved
by the Institutional Review Boards of the Mayo Clinic, the Cancer
Institute of the Chinese Academy of Medical Sciences, the
University of Leuven and the US National Cancer Institute. The
demographic information, clinical features and follow-up information on the patients have been reported previously [32]. These
HCC samples are different from those in our other previous
reports [11]. The details of microarray gene expression profiling
have also been described in the previous paper [40]. The data
have been deposited at Gene Expression Omnibus (GEO/
GPL1528, GEO/GPL1529, GEO/GSE1897, GEO/GSE1898
and GEO/GSE4024). Briefly, total RNAs were isolated from
frozen liver tissue using CsCl density-gradient centrifugation.
20 mg of total RNA from tissues was used to derive fluorescently
(Cy-5 or Cy-3) labeled cDNA. We carried out at least two
hybridizations for each tissue using a dye-swap strategy to
eliminate dye-labeling bias. Specimens were analyzed at the US
National Cancer Institute using the Human Array-Ready Oligo
Set (Version 2.0) containing 70-mer probes of 21,329 genes from
Qiagen (Valencia, CA).

in HCC cells. (A) At the levels of both mRNA and protein, GLI1
expression is increased by GLI1 expressing plasmid in Huh7 cells
and decreased by GLI1 ASO in SNU398 cells. (B) GLI reporter
luciferase activity is increased by GLI1 expressing plasmid in
Huh7 cells and decreased by GLI1 ASO in SNU398 cells.
(TIF)
Figure S4 SNAI1 is a transcriptional target of GLI1 in
HCC cells. (A) As measured by qRT-PCR, SNAI1 expression is
decreased by knockdown of GLI1 in SNU449 and SNU475 cells
(B) qRT-PCR confirm the efficiency of GLI1 overexpression and
knockdown in the indicated HCC lines.
(TIF)

GLI1 induces the EMT in HCC ells. (A) qRTPCR showing that TGFb1 induces the expression of SNAI1 in
SNU398. (B-C) As assessed by qRT-PCR, overexpression of GLI1
decreases E-cadherin mRNA expression in SNU423 cells (B) and
increases the mRNA expression of Vimentin in SK-HEP-1 cells
(C), while knockdown of GLI1 increases E-cadherin mRNA
expression and decreases the mRNA expression of both Ncadherin and Vimentin in SNU475 cells. (D) mRNA expression in
SNU475 shows that knockdown of GLI1 increase the expression
of E-cadherin levels and dimished the expression of N-Cadherin
and Vimentin.
(TIF)
Figure S5

Statistical Analysis
All data are expressed as means and standard errors of the
mean. Differences between groups were compared with the MannWhitney test. Differences between the Kaplan-Meier curves of
HCC patients with high and low/no-GLI1 expression in the HCC
tissue in comparison with the adjacent benign tissue were analyzed
using the log rank test.

Table S1 Demographic information and clinical features of patients from GLI1 high expresser group and
GLI1 low/non-expresser group.
(DOC)
Table S2 Demographic information and clinical features of patients from high GLI1 group and low GLI1
group.
(DOC)

Supporting Information
Figure S1 GLI1 is differentially regulated in HCC cell
lines. Five of the tested HCC cell lines (PLC/PRF5, SNU182,
SNU398, SNU449, and SNU475) express GLI1 mRNA at a
higher level than normal human hepatocytes. SNU398 is the
highest expressing cell line and expresses GLI1 mRNA at over 55times the level in normal hepatocytes. Other HCC cell lines
including Huh7, SK-HEP-1, Hep3B, SNU387, SNU423 and the
hepatoblastoma cell line HepG2 express lower GLI1 mRNA levels
than normal human hepatocytes.
(TIF)
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Figure S2 GLI1 protein expression in HCC cell lines.

Western blotting confirms that GLI1 protein expression correlates
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